晚期子宫内膜癌患者静脉血栓栓塞的发生率与发生时机
这项单机构回顾性研究纳入84例接受新辅助化疗(NACT,n=34)或辅助化疗(n=50)的III-IV期子宫内膜癌患者,总体静脉血栓栓塞(VTE)发生率为27.4%(95% CI,18.8-38.0%)。接受NACT者中,NACT期间VTE发生率为14.3%,持续化疗期间为16.7%;术后及辅助治疗期间发生率均低于10.0%。Khorana评分对VTE预测能力差,中危患者中52.0%发生VTE。
要点
- 晚期子宫内膜癌患者总体VTE发生率为27.4%(95% CI,18.8-38.0%)。
- NACT期间VTE发生率为14.3%,持续化疗期间为16.7%。
- Khorana评分预测VTE能力差,中危患者中52.0%发生VTE。
核心结论
- 晚期子宫内膜癌患者VTE风险较高,且Khorana评分预测能力差,需改进风险分层与预防策略。
研究设计与样本
- 单机构回顾性研究,纳入84例接受新辅助化疗(n=34)或辅助化疗(n=50)的III-IV期子宫内膜癌患者。
主要发现
- 总体VTE发生率为27.4%(95% CI,18.8-38.0%)。
- 接受NACT者中,NACT期间VTE发生率为14.3%,持续化疗期间为16.7%。
- 术后及辅助治疗期间VTE发生率均低于10.0%。
- Khorana评分对VTE预测能力差,中危患者中52.0%发生VTE。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为单机构回顾性研究。
- 原文指出需更大规模研究来评估风险分层优化及全身治疗期间VTE预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with advanced endometrial cancer (EC) are at risk for venous thromboembolism (VTE), though risk by treatment phase remains unclear. This single-institution retrospective study evaluated 84 patients receiving neoadjuvant chemotherapy (NACT, n=34) or adjuvant chemotherapy (n=50) for stage III-IV EC. Overall VTE incidence was 27.4% (95% CI, 18.8-38.0%). Among patients receiving NACT, VTE occurred in 14.3% during NACT and in 16.7% during ongoing chemotherapy. Postoperative and adjuvant treatment rates were less than 10.0%. Khorana score was a poor predictor of VTE, with 52.0% of intermediate-risk patients developing VTE. These findings highlight the need for improved VTE risk-reduction strategies, including larger studies to evaluate optimization of risk stratification and VTE prophylaxis during systemic therapy for advanced EC.
引用
- Llanora JD, Uppal S, McLaughlin HD, et al. Incidence and Timing of Venous Thromboembolism in Patients With Advanced Endometrial Cancer. Obstet Gynecol. 2025. PMID: 40532211. doi:10.1097/AOG.0000000000005978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。